GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

quecitinib   Click here for help

GtoPdb Ligand ID: 14064

Synonyms: QY-201 | QY201 | VVN-461 | VVN461
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Quecitinib is the INN for a Janus kinase inhibitor with anti-inflammatory potential (INN proposed list 133, 10th July 2025). We have mapped this to the disclosed structure of clinical lead QY201, which is declared as an orally administered dual JAK1/TYK2 inhibitor [1]. The structure also matches the compound named VVN461 in patent WO2024221524A1 [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 87.25
Molecular weight 324.38
XLogP -0.44
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@H](C1=NC2=CN=C3C(=C2N1N4CCC(CC#N)CC4)C=CN3)O
Isomeric SMILES O[C@H](C)C1=NC=2C(=C3C(=NC2)NC=C3)N1N4CCC(CC4)CC#N
InChI InChI=1S/C17H20N6O/c1-11(24)17-21-14-10-20-16-13(3-7-19-16)15(14)23(17)22-8-4-12(2-6-18)5-9-22/h3,7,10-12,24H,2,4-5,8-9H2,1H3,(H,19,20)/t11-/m1/s1
InChI Key LUQHXRXPKKQUKV-LLVKDONJSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Wang JY, Gao YH, Ruan ZR, Yang DD, Li H, Qiao SD, Li JH, You X, Shi J, Jiang B. (2025)
The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects.
J Clin Pharmacol, [Epub ahead of print]. [PMID:40424417]
2. Xia E, Han Q, Shen W, Li Y, Gao H. (2024)
Ophthalmic composition for treating non-infectious inflammatory diseases.
Patent number: WO2024221524A1. Assignee: Weimo Biotechnology (Zhejiang) Co., Ltd.. Priority date: 25/05/2023. Publication date: 31/10/2024.